RIN1在人膀胱尿路上皮癌中的表达

目的研究RIN1在人膀胱尿路上皮癌中的表达。方法分别应用免疫蛋白印迹技术和实时定量PCR技术检测RIN1蛋白和RIN1 m RNA在人膀胱尿路上皮癌及癌旁组织中的表达。结果 Real-time PCR结果发现,在15对新鲜的膀胱尿路上皮癌及癌旁组织中,有12对的癌组织中RIN1表达高于癌旁组织。在膀胱尿路上皮癌组织中,RIN1的m RNA表达平均倍数为10.61±5.42,癌旁组织中,RIN1的m RNA平均倍数为4.31±1.77,P0.05。Western blot法结果认证了RIN1在膀胱尿路上皮癌组织中的表达是升高的。结论 RIN1在膀胱尿路上皮癌组织中的m RNA和蛋白的表达水平高于癌旁组织。     

miR-1在膀胱尿路上皮癌中的表达及其功能

目的研究miR-1在膀胱尿路上皮癌中的表达和临床意义,探讨miR-1在膀胱癌发病的作用。方法应用real-time PCR方法分别检测60例配对的新鲜膀胱尿路上皮癌及癌旁正常组织中miR-1的表达,统计分析miR-1表达差异与临床病理因素间的关系,应用CCK8法检测miR-1对膀胱癌T24细胞增殖能力的影响。结果miR-1在膀胱癌组织较癌旁正常组织中表达水平显著降低,而且肌层浸润性膀胱癌(T2-T4)患者组织中的miR-1表达显著低于非肌层浸润性膀胱癌组织(Ta-T1)。miR-1异常低表达与膀胱癌复发或转移、临床分期及病理分级密切相关,miR-1能够抑制膀胱癌T24细胞的增殖能力。结论miR-1在膀胱癌的发病过程中可能发挥着重要作用,可能成为未来膀胱癌治疗的新靶点及预后预测因子。     

膀胱尿路上皮癌中LC3B与SQSTM1的表达及其临床意义

目的 探讨微管相关蛋白1轻链3β(microtubule-asso-ciated protein 1 light chain 3β,LC3B)及选择性自噬接头蛋白1(sequestosome 1,SQSTM1)在膀胱尿路上皮癌组织中的表达及其临床意义.方法 采用免疫组化MaxVision法检测LC3B与SQSTM1在4...     

膀胱尿路上皮癌HER2表达及临床病理分析

目的 探讨膀胱尿路上皮癌(bladder urothelial carcinoma, BUC)中HER2的表达情况,并分析其临床意义。方法 收集膀胱非浸润性低级别BUC 27例、非浸润性高级别BUC 5例、浸润性高级别BUC 60例,采用免疫组化MaxVision法法检测各组织样本中HER2蛋白的表达,并分析HER2表达与临床病理特征的关系。通过GEPIA数据库或直接在肿瘤基因组图谱(The Cancer Genome Atlas, TCGA)中分析HER2(ERBB2)表达与BUC的关系。结果 浸润性高级别BUC中HER2 2+/3+表达率(26.67%,16/60)显著高于非浸润性低级别BUC(7.41%,2/27)和非浸润性高级别BUC(0,0/5)(P<0.05)。多灶性浸润性高级别BUC中HER2 2+/3+表达率(75.00%,6/8)显著高于单灶性患者(19.23%,10/52)(P<0.05)。各组织学亚型中HER2 2+/3+表达率差异有统计学意义(P<0.05),其中普通型为30%(6/20)、腺样分化型为57.14%(4/7)、微乳头型为66.6...     

膀胱尿路上皮癌中LRG1和TGF-β1的表达及临床病理意义

目的 探讨富亮氨酸α2糖蛋白1（leucine-rich alpha-2-glycoprotein 1, LRG1）及转化生长因子beta 1（transforming growth factor-beta 1, TGF-β1）在膀胱尿路上皮癌（bladder urothelial carcinoma, BUC）组织中的表达及意义。方法 采用免疫组化SP法检测LRG1、TGF-β1及Ki-67在64例BUC组织及25例癌旁组织中的表达,分析LRG1、TGF-β1在各组间表达的差异及相关性。结果 LRG1在BUC组织中强阳性27例（42.19%）,癌旁组织中强阳性仅2例（8.00%）,两组相比差异有统计学意义（P<0.05）;TGF-β1在BUC组织中阳性49例（76.56%）,在癌旁组织中阳性10例（40.00%）,差异有统计学意义（P<0.05）;相关性分析显示,LRG1与TGF-β1表达呈正相关（r²=0.658 2,P<0.05）;LRG1、TGF-β1表达均与BUC病理学分级、浸润深度及Ki-67增殖指数相关（P<0.05）。结论 ...     

UroplakinⅢ与Twist在膀胱尿路上皮癌中的表达及临床意义

目的 探讨UroplakinⅢ(UPⅢ)、Twist在膀胱尿路上皮癌中的表达及临床意义.方法 采用免疫组化SP法检测UPⅢ和Twist的表达.结果 UPⅢ在140例膀胱尿路上皮癌组的表达阳性率为15.7％ (22/140)低于70例正常膀胱粘膜组71.4％ (50/70),差异有统计学意义(P＜0.05).Twist在...     

pT1期膀胱尿路上皮癌的病理诊断及分期

膀胱尿路上皮癌的分期是最重要的预后因子。WHO将浸润性膀胱尿路上皮癌定义为肿瘤侵透基底膜。膀胱癌TNM分期系统（2002）将膀胱的pT1期肿瘤定义为肿瘤浸润固有膜,但未侵及肌层。尽管临床上常将pT1和pTa期（非浸润性肿瘤）合称为“浅表性”膀胱肿瘤,但pT1期肿瘤的预后要比pTa期差,因此正确诊断pT1期肿瘤对于选择治疗方案和估计预后非常重要。[第一段]     

膀胱浆细胞样尿路上皮癌1例

患者男性,70岁.无明显诱因出现肉眼血尿4个月余,伴尿频、尿痛,遂于2019年4月就诊于我院.男性泌尿系超声示膀胱壁低回声伴环状钙化,增强CT示膀胱左侧后壁局部不均匀增厚隆起(图1);腹膜后大血管旁多发淋巴结肿大.膀胱镜检查见膀胱左侧壁有一宽基息肉状新生物,膀胱内广泛滤泡样及鱼鳞样改变,侵及膀胱颈口及双侧输尿管开口.     

miR-21及miR-300在膀胱尿路上皮癌中的表达意义分析

目的分析膀胱尿路上皮癌中的miRNA-21及miRNA-300的差异表达,研究miRNA在该疾病中的致病机制。方法选取我院于2015年1月-2018年1月间我院收治的40例膀胱尿路上皮癌患者作为实验组,选取同期收治的20例泌尿系统良性疾病患者作为对照组,采用RT-PCR方法对两组患者血清及尿液标本中的miR-21、miR-300表达含量进行比较。结果尿路上皮癌组中的血清及尿液miR-21、miR-300表达含量明显高于良性疾病组,组间比较差异有统计学意义(P0.05),浸润性膀胱尿路上皮癌组中的血清miR-21表达含量明显高于良性疾病组(P0.05),尿液miR-21及miR-300组间比较差异无统计学意义(P0.05),高级别膀胱尿路上皮癌组中的血清及尿液miR-21、miR-300表达含量明显高于良性疾病组(P0.05)。血清及尿液中的miR-21及miR-300水平在年龄、性别之间差异均无统计学意义(P0.05)。结论 miR-21、miR-300在膀胱尿路上皮癌组织中高表达,其可能对肿瘤的发生、发展及转移有一定影响,进而为膀胱尿路上皮癌的治疗提供一个新的潜在靶点。     

Cytopathologic differential diagnosis of low‐grade urothelial carcinoma and reactive urothelial proliferation in bladder washings: a logistic regression analysis

Conventional cytomorphologic assessment is the first step to establish an accurate diagnosis in urinary cytology. In cytologic preparations, the separation of low‐grade urothelial carcinoma (LGUC) from reactive urothelial proliferation (RUP) can be exceedingly difficult. The bladder washing cytologies of 32 LGUC and 29 RUP were reviewed. The cytologic slides were examined for the presence or absence of the 28 cytologic features. The cytologic criteria showing statistical significance in LGUC were increased numbers of monotonous single (non‐umbrella) cells, three‐dimensional cellular papillary clusters without fibrovascular cores, irregular bordered clusters, atypical single cells, irregular nuclear overlap, cytoplasmic homogeneity, increased N/C ratio, pleomorphism, nuclear border irregularity, nuclear eccentricity, elongated nuclei, and hyperchromasia (p ? 0.05), and the cytologic criteria showing statistical significance in RUP were inflammatory background, mixture of small and large urothelial cells, loose monolayer aggregates, and vacuolated cytoplasm (p ? 0.05). When these variables were subjected to a stepwise logistic regression analysis, four features were selected to distinguish LGUC from RUP: increased numbers of monotonous single (non‐umbrella) cells, increased nuclear cytoplasmic ratio, hyperchromasia, and presence of small and large urothelial cells (p = 0.0001). By this logistic model of the 32 cases with proven LGUC, the stepwise logistic regression analysis correctly predicted 31 (96.9%) patients with this diagnosis, and of the 29 patients with RUP, the logistic model correctly predicted 26 (89.7%) patients as having this disease. There are several cytologic features to separate LGUC from RUP. Stepwise logistic regression analysis is a valuable tool for determining the most useful cytologic criteria to distinguish these entities.     

SOX4 expression levels in urothelial bladder carcinoma

High levels of SOX4 gene expression have been reported in a variety of human cancers. The protein may function in the apoptosis pathway, leading to cell death as well as to tumorigenesis. The aim of this study was to investigate the levels of SOX4 expression in bladder cancer. Urinary bladder tumor samples were obtained from 57 bladder cancer and 13 normal bladder biopsies. The levels of SOX4 expression in bladder cancer were determined by immunohistochemistry and real-time PCR. SOX4 gene expression was increased 2.2 times in bladder tumors as compared with normal tissue. The presence of protein was confirmed by immunostaining. There were significant differences between immunostaining of bladder tumors and normal bladder tissue (P = 0.001). The present data suggest that SOX4 gene may have a role in bladder cancer tumorigenesis.     

乳腺癌中RIN1的表达及临床意义

目的 研究RIN1在乳腺癌中的表达,分析它与乳腺癌预后的关系.方法 用免疫组化SP法检测85例乳腺癌和20例乳腺良性病变组织中RIN1的表达,并对85例乳腺癌病例进行随访;用real-time PCR和Western blot 法检测RIN1在20例乳腺癌和癌旁组织中的表达.Kaplan-Meier分析生存结果.结果 85例乳腺癌标本中RIN1有不同程度表达,其中44例高表达,乳腺癌中RIN1的表达明显高于非癌组织(P＜0.05);RIN1高表达与肿瘤最大直径、组织学分级、肿瘤家族史成正相关(P＜0.05);RIN1高表达患者的平均生存时间低于RIN1低表达患者(P＜0.05);RIN1高表达影响肿瘤无病生存率(P＜0.05).20例标本中RIN1的mRNA及蛋白在乳腺癌的表达明显高于癌旁组织(P＜0.05).结论 RIN1影响乳腺癌的发生发展,其高表达RIN1可能成为判断乳腺癌预后的一个标志物.     

High expression of Notch ligand Jagged2 is associated with the metastasis and recurrence in urothelial carcinoma of bladder

Background: The Notch signaling pathway is closely related with human organ development and tumorgenisis. Jagged2 is among the most popular topic in Notch studies currently. Recent studies found its vital role in tumor metastasis in breast cancer; however, its expression profile and its prognostic value in urothelial carcinoma of bladder have not been investigated. Methods: Immunohistochemistry was used to detect the expression of Jagged2 in 120 bladder urothelial carcinoma. Moreover, the expression of Jagged2 was analyzed by Western blot in 60 bladder urothelial carcinoma and 20 normal epithelial tissues. MTT assay and flow cytometry and transwell assay were used to examine the proliferative and invasive ability of bladder cancer cells with the treatment of GSIXX (the inhibitor of Jagged2). Prognostic value of Jagged2 expression and its correlation with tumor metastasis and recurrence were evaluated, and the proliferative and invasive ability and cell cycle process of the bladder cancer cells were detected as well. Results: There was a significantly higher Jagged2 expressions in bladder urothelial carcinoma and highly invasive bladder T24 cells than those in bladder normal tissues and the superficial bladder BIU-87 cells. Jagged2 expression was positively correlated with histological grade, p T stage, recurrence, and metastasis. With the increasing concentration of GSIXX, we found that not only the cell proliferation and invasion activity decreased significantly, but also the cell cycle was blocked at G₂/M stage. Conclusions: Jagged2 expression status was closely correlated with important histopathologic characteristics (grades and stages) and the recurrence and metastasis of bladder urothelial carcinomas. Furthermore, Jagged2 played an important function on the bladder cancer cells’ proliferation by regulating the cancer cell cycle from G₁/S to G₂/M and probably promoted the invasion and metastasis of bladder cancer.     

Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy

Cisplatin has been the cornerstone of the chemotherapy regimen for urothelial carcinoma. Excision repair cross-complementation group 1 (ERCC1) is a key component of the platinum-DNA repair machinery responsible for nucleotide excision repair. Recent reports have suggested that ERCC1 is a predictive and prognostic marker in solid cancers treated with platinum-based chemotherapy. We performed this study to determine whether or not immunohistochemical expression of ERCC1 can predict objective tumor response and cancer-specific survival in patients with advanced urothelial carcinoma treated with cisplatin-based chemotherapy. We performed a retrospective analysis of 89 patients with advanced or recurrent urothelial cancer, who had undergone treatment at Samsung Medical Center between May 2001 and August 2007. Pretherapeutic biopsy samples from 89 patients with a known tumor response were available. ERCC1 expression was assessed by immunohistochemistry. Of the 89 patients, ERCC1 expression was positive in 49 patients (55%). The overall response rate after chemotherapy was 68.5% (95% CI 54.8-74.8%). Among 61 patients who obtained a response, 27 were negative for ERCC-1 expression and 34 were positive (p = 0.61). Median duration of follow-up was 53.7 months (range 14.4-152.3 months). Progression-free survival (PFS) was 10.6 months for ERCC-1-negative patients and 8.4 months for ERCC-1-positive patients (p = 0.03); the difference in overall survival between patients with ERCC-1-negative tumors and ERCC-1-positive tumors (p = 0.73) was not statistically significant. Other than ERCC1 expression, there was no independent prognostic factor for PFS. These results suggest a negative contribution by ERCC1expression to PFS in metastatic urothelial carcinoma patients treated with cisplatin-based chemotherapy.     

Beclin 1 and bcl-2 expressions in bladder urothelial tumors and their association with clinicopathological parameters

Beclin 1 plays a critical role in the regulation of autophagy, apoptosis, differentiation, as well as in the development and progression of cancer. The aim of this study was to examine the expression of beclin 1 and bcl-2 in bladder urothelial tumors, and to investigate the relationship between these two markers and clinicopathological parameters. Our study included 84 bladder urothelial tumors and 10 non-tumoral bladder tissues. Immunohistochemistry was performed on tissue microarray (TMA) sections and was evaluated semiquantitatively on the basis of the percentage of positively stained cells (proportion) and staining intensity. A significant association was found between the expression score of beclin 1 and pT stages of the urothelial tumors (p = 0.012). Also, the level of beclin 1 expression inversely correlated with histological grade and pT stages (p = 0.009, r = −0.284; p = 0.001, r = −0.361, respectively). The bcl-2 expression level positively correlated with histological grade and pT stages of the urothelial tumors (p = 0.026, r = 0.243; p < 0.0001, r = 0.491, respectively). In addition, the level of beclin 1 expression tended to be inversely correlated with the bcl-2 expression level in urothelial tumors (p = 0.055, r = −0.210). According to our data, down-regulation of beclin 1 expression and also bcl-2 overexpression seem to play an important role in the progression and aggressiveness of bladder urothelial tumors.